Company news

Lyell Immunopharma, Inc. news in 2025

Lyell Immunopharma, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

December 7, 2025

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

November 12, 2025

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

November 11, 2025

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

November 10, 2025

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

November 3, 2025

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

September 3, 2025

Lyell Immunopharma Announces Participation in September Investor Conferences

September 2, 2025

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

August 12, 2025

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

July 25, 2025

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

June 23, 2025

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

June 17, 2025

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

June 9, 2025

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

June 4, 2025

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 13, 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

May 1, 2025

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

April 15, 2025

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

March 11, 2025

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

February 18, 2025

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

January 8, 2025

Decks in 2025